Testing a new combination treatment for aggressive lymphoma that has returned

Plain-English translation of NCT06806033 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new treatment approach for aggressive B-cell lymphoma—a cancer of the immune system—that has either returned after treatment or stopped responding to it. The trial combines three medications: (a newer type of immunotherapy), , and . The researchers are specially designing the way you take these medications and the monitoring schedule so that treatment can happen safely in an outpatient clinic rather than requiring hospital stays.

Patients whose lymphoma comes back or doesn't respond to standard treatments have limited options and often face poor outcomes. This study aims to see whether this new medication combination—with careful attention to managing side effects—can give patients a more effective treatment option that they can receive as outpatients.

Do you qualify?

You likely qualify if…

you have been diagnosed with aggressive B-cell lymphoma (specific types include DLBCL, high-grade B-cell lymphoma, or double-hit lymphoma) confirmed by a tissue biopsy
your lymphoma has either returned after previous treatment or has stopped responding to your last therapy
you have received at least one prior line of cancer treatment
you have at least one measurable tumor on a CT scan that doctors can track
you are well enough to receive outpatient treatment (ECOG score of 0, 1, or 2)
you have adequate kidney and blood cell function

You likely don't qualify if…

you have received prior treatment with glofitamab or similar bispecific antibodies
you have had previous treatment with gemcitabine or oxaliplatin
you have significant nerve damage or numbness in your hands or feet
you have a history of severe allergic reactions to monoclonal antibodies or similar medications
you have lymphoma in the brain or spinal cord that has not been completely treated and confirmed in remission

What participation looks like

You will receive an initial treatment with a medication called , followed by cycles of the combination treatment (, , and ) given in an outpatient clinic setting. The study uses a special schedule and steroid premedication to help manage side effects so you can be treated without staying overnight in the hospital. After the combination phase, you may continue with alone. You will have regular visits for blood tests, scans, and check-ups to monitor how the treatment is working and how you are tolerating it.

AI-generated summary from trial data · Aug 20, 2026 · Not medical advice

Trial locations(53 sites)

United States

Alaska Oncology & Hematology, LLC, Anchorage, Alaska

Community Cancer Institute (CCI), Clovis, California

Providence Medical Foundation, Fullerton, California

Los Angeles Cancer Network, Glendale, California

Valkyrie Clinical Trials, Los Angeles, California